Eli Lilly and Co's Zepbound has been approved by the FDA for the treatment of obstructive sleep apnea.

① The FDA in the USA approved Eli Lilly and Co's weight loss medication Zepbound on Friday for the treatment of obstructive sleep apnea (OSA), making it the first drug approved for directly treating this common sleep disorder; ② The active ingredient in Zepbound is Tirzepatide, which was initially used to treat type 2 diabetes, namely Eli Lilly and Co's Mounjaro.

cls.cnDec 22 11:45

U.S. stocks closed higher | The three major Indexes collectively rose, with the Nasdaq increasing by nearly 1%; chip stocks surged, with Broadcom and Taiwan Semiconductor rising over 5%, and NVIDIA increasing nearly 4%.

① The Nasdaq China Golden Dragon Index rose by 0.91%; ② The PHLX Semiconductor Index rose by over 3%; ③ MicroStrategy purchased 5,262 Bitcoins; ④ The suspect in the UnitedHealth executive's murder case pleaded not guilty.

cls.cn07:07

Citi Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $1,250

Futu NewsDec 21 18:33 · Ratings

Sector Update: Health Care Stocks Advance Late Afternoon

MT Newswires04:59

Ely Lilly Shares Are Trading Higher After the FDA Approved the Company's Zepbound, a Weight Loss Drug Designed to Treat Moderate-to-severe Obstructive Sleep Apnea in Adults With Obesity.

Benzinga04:45

Sector Update: Health Care

MT Newswires04:34